Trial Profile
A Randomized Phase III Clinical Study of Entinostat/Placebo in Combination With Exemestane in Chinese Patients With Hormone Receptor-positive Advanced Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Entinostat (Primary) ; Exemestane (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Eddingpharm; EOC Pharma
- 07 Jul 2021 Planned End Date changed from 1 Aug 2021 to 1 Mar 2023.
- 07 Jul 2021 Planned primary completion date changed from 1 Feb 2021 to 1 Jul 2021.
- 07 Jul 2021 Status changed from recruiting to active, no longer recruiting.